11/21
09:53 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its "outperform" rating re-affirmed by analysts at William Blair.
11/19
07:02 pm
exas
Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]
11/19
04:11 pm
exas
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]
Low
Report
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]
11/18
08:35 am
exas
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test [Yahoo! Finance]
Low
Report
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test [Yahoo! Finance]
11/18
08:12 am
exas
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community [Yahoo! Finance]
Low
Report
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community [Yahoo! Finance]
11/18
04:37 am
exas
Cancer Profiling Market Research Report 2024 - Global Forecasts to 2029: Biomarker-Based Tumor Profiling and Point-of-Care Innovations Driving Growth [Yahoo! Finance]
Low
Report
Cancer Profiling Market Research Report 2024 - Global Forecasts to 2029: Biomarker-Based Tumor Profiling and Point-of-Care Innovations Driving Growth [Yahoo! Finance]
11/16
07:42 am
exas
Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock [Yahoo! Finance]
Low
Report
Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock [Yahoo! Finance]
11/13
04:12 pm
exas
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]
Low
Report
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]
11/13
01:00 pm
exas
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Low
Report
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
11/11
08:09 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.
11/6
02:11 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.
11/6
02:10 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.
11/6
01:10 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $95.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $95.00 to $75.00. They now have a "buy" rating on the stock.
11/6
01:10 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at BTIG Research from $82.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at BTIG Research from $82.00 to $65.00. They now have a "buy" rating on the stock.
11/6
01:10 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Stifel Nicolaus from $82.00 to $67.00. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Stifel Nicolaus from $82.00 to $67.00. They now have a "buy" rating on the stock.
11/6
12:42 pm
exas
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount [Yahoo! Finance]
Low
Report
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount [Yahoo! Finance]
11/6
12:23 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Evercore ISI from $80.00 to $60.00. They now have an "outperform" rating on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Evercore ISI from $80.00 to $60.00. They now have an "outperform" rating on the stock.
11/6
12:23 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $75.00 to $65.00. They now have a "buy" rating on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $75.00 to $65.00. They now have a "buy" rating on the stock.
11/6
12:23 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at TD Cowen from $90.00 to $82.00. They now have a "buy" rating on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at TD Cowen from $90.00 to $82.00. They now have a "buy" rating on the stock.
11/6
10:20 am
exas
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point [Yahoo! Finance]
Medium
Report
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point [Yahoo! Finance]
11/6
09:22 am
exas
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut [Yahoo! Finance]
Medium
Report
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut [Yahoo! Finance]
11/6
09:17 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Benchmark Co. from $67.00 to $65.00. They now have a "buy" rating on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Benchmark Co. from $67.00 to $65.00. They now have a "buy" rating on the stock.
11/6
09:16 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Craig Hallum from $82.00 to $65.00. They now have a "buy" rating on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Craig Hallum from $82.00 to $65.00. They now have a "buy" rating on the stock.
11/6
08:07 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Robert W. Baird from $70.00 to $67.00. They now have an "outperform" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Robert W. Baird from $70.00 to $67.00. They now have an "outperform" rating on the stock.
11/6
02:33 am
exas
Exact Sciences Corp (EXAS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Medium
Report
Exact Sciences Corp (EXAS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]